P3 Health Partners Inc. (PIII) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] P3 Health Partners Inc (PIII) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, P3 Health Partners is a physician-led healthcare services company that helps manage patient populations and medical costs, but right now the story is less about a stable business and more about whether a sharp turnaround is finally becoming real. > **📍 Basic Profile** > > Market Cap **$0.03 billion** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$11.29** > **⚡ 3 Things You Should Know** > > 1. 📈 Turnaround finally showed up in the latest quarter: after a long stretch of ugly losses, P3 posted a major earnings beat and raised guidance, which is why the stock exploded upward—basically, the market is reacting to “maybe this business is fixable after all.” > > 2. ⚠️ The balance sheet is still the weak spot: liquidity is tight, leverage is high, and cash flow remains negative, so even with better operations, this is not yet a financially comfortable company. > > 3. 💸 The stock still screens “cheap” on sales, but that can be misleading: when margins are negative and earnings are unstable, a low P/S ratio often means the market still doubts the business model, not that the stock is automatically a bargain. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -10.14%, gross margin -4.12%, still loss-making on a TTM basis | > | Growth Rate | Steady📈 | 3-year revenue growth 11.61%, 5-year 24.62%, but near-term execution has been uneven | > | Financial Health | Tight🧡 | Debt/equity 2.04, current ratio 0.24, interest coverage negative | > | Valuation | Cheap | P/S 0.02x, but PE unavailable because earnings remain inconsistent | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** P3 Health Partners provides population health management and care coordination services to patients and payer/provider networks, making money by managing medical spending and capturing revenue tied to healthcare services and value-based care arrangements. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Population health / healthcare services | [Data unavailable] | ↑ | Revenue base appears sizable, with FY2026 sales outlook around $1.5B+ | | Other segments | [Data unavailable] | [Data unavailable] | The provided dataset does not break revenue into business lines | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | -4.12% | Below Average | This is the big red flag: core economics are still weak on a trailing basis | | Net Margin | -10.14% | Below Average | The company is still losing money overall, even after recent improvement | | ROE | -191.97% | Below Average | Extremely negative ROE usually reflects ongoing losses plus a thin equity base | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth, but volatile quality | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | Improving sharply in latest quarter | **Growth Quality:** > What’s interesting is that this is not a clean high-growth story. Revenue has grown over the multi-year period, but the real issue has been whether that revenue can turn into profits. The latest quarter looked much better—Q1 2026 reportedly swung to net income of $3M versus a $44M loss a year ago, and EPS beat estimates by a wide margin. In other words, the latest growth/improvement looks more operationally meaningful than just “buying growth,” but one quarter alone doesn’t fully erase the earlier pattern of misses. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a business with a decent top line but very little cash cushion—still paying bills under pressure while trying to prove the turnaround is real. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | Debt/Equity 2.04 | <60% safe | ⚠️High | | Current Ratio | 0.24 | >1.5 healthy | 🚨Dangerous | | Cash Flow | -$7.38/share | >0 | 🚨Negative | Worth noting: interest coverage is **-4.83**, which means operating earnings are not currently covering interest expense in a healthy way. That’s one of the clearest signs that the financial structure remains fragile. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.52 - 52-Week High: $14.35 - Current: $11.29, **Very close to high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(76% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | P/S 0.02x | Industry avg [Data unavailable] | Likely low, but peer context not provided | **What the Current Valuation is Betting On:** > Basically, the stock’s recent jump suggests the market is now betting on a turnaround rather than valuing P3 on current profitability. At this price, investors seem to be saying: “If the company can keep narrowing losses, stabilize liquidity, and hit its guidance, this could re-rate higher.” If that turnaround stalls, the stock could give back gains quickly. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-14 | Q1 2026 results beat expectations; narrower loss / reported turnaround and raised guidance | Positive — this is the main driver behind the recent surge and improves confidence in execution | | 2026-05-14 | Stock surged sharply after hours following earnings | Positive — shows sentiment was very bearish and results surprised the market | | 2026-05-14 | FY2026 sales guidance narrowed to $1.50B-$1.65B vs prior $1.50B-$1.70B | Neutral — still broadly in line with expectations, but the narrower top end hints management is staying somewhat cautious | | 2026-05-15 | Lake Street maintained Buy and raised price target to $14 | Positive — reflects improving Street confidence after the quarter | | 2026-04-01 | TD Cowen maintained Hold and cut price target to $3 | Negative — a reminder that sentiment was recently much weaker and not all analysts are convinced | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | -4.12% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -10.14% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -191.97% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ (3Y CAGR 11.61%) | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | -$3.58 | $0.32 | +109.0% Beat 😀 | | 2025-12-31 | -$9.65 | -$23.02 | -138.4% Miss 😟 | | 2025-09-30 | -$6.16 | -$9.67 | -57.0% Miss 😟 | | 2025-06-30 | -$4.83 | -$6.23 | -28.9% Miss 😟 | **Earnings Trend Interpretation:** The pattern here is actually pretty dramatic: three straight misses followed by one huge beat. That usually means either the business has genuinely improved very quickly, or expectations had become so low that even a modest stabilization looked huge. Either way, the latest quarter matters a lot—but the next 1–2 quarters matter even more, because they tell you whether this was a one-off rebound or the start of a consistent reset. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 6 firms | 75% | | Hold | 2 firms | 25% | | Sell | 0 firms | 0% | **Target Price:** $3 ~ $14 (Median [Data unavailable]) **vs Current Price:** ranges from meaningful downside to modest upside, depending on which analyst you trust **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided, so there’s no useful read-through here. If insiders were buying after the turnaround quarter, that would be encouraging; if they were selling heavily, that would temper the optimism. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Liquidity Risk:** Current ratio of 0.24 and negative cash flow suggest limited short-term flexibility → If operations wobble again, it could lead to financing pressure or dilution risk. 2. **Turnaround Risk:** The stock is reacting to one strong quarter after multiple earnings misses → If upcoming quarters fail to confirm the improvement, it could lead to a sharp sentiment reversal. 3. **Margin Risk:** Gross and net margins are still negative on a trailing basis → If medical cost management or reimbursement economics don’t improve further, it could lead to ongoing losses despite revenue scale. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** P3 Health Partners is a value-based healthcare operator trying to turn a large revenue base into a consistently profitable business. > > **Key strength:** The latest quarter was a real attention-grabber, with a major earnings beat, apparent profit improvement, and better guidance driving a big re-rating in the stock. > > **Key risk:** The balance sheet is still stretched, and because the stock has already run close to its 52-week high, any stumble in the turnaround could be punished fast. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis